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ABSTRACT
Pimozide, an antipsychotic drug of the diphenylbutylpiperidine class, has been 
shown to suppress cell growth of breast cancer cells in vitro. In this study we further 
explore the inhibitory effects of this molecule in cancer cells. We found that Pimozide 
inhibited cell proliferation in a dose- and time-dependent manner in MDA-MB-231 
breast cancer cells and A549 lung cancer cells. Furthermore, we found that Pimozide 
also promoted apoptosis as demonstrated by cell cycle arrest and induction of double-
strand DNA breaks but did not result in any effect in the non-transformed MCF10A 
breast cell line. In order to shed new lights into the molecular pathways affected by 
Pimozide, we show that Pimozide downregulated RAN GTPase and AKT at both protein 
and mRNA levels and inhibited the AKT signaling pathway in MDA-MB-231 breast 
cancer cells. Pimozide also inhibited the epithelial mesenchymal transition and cell 
migration and downregulated the expression of MMPs. Administration of Pimozide 
showed a potent in vivo antitumor activity in MDA-MB-231 xenograft animal model and 
reduced the number of lung metastases by blocking vascular endothelial growth factor 
receptor 2. Furthermore, Pimozide inhibited myofibroblast formation as evaluated 
by the reduction in α-smooth muscle actin containing cells. Thus, Pimozide might 
inhibit tumor development by suppressing angiogenesis and by paracrine stimulation 
provided by host reactive stromal cells. These results demonstrate a novel in vitro and 
in vivo antitumor activity of Pimozide against breast and lung cancer cells and provide 
the proof of concept for a putative Pimozide as a novel approach for cancer therapy.
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INTRODUCTION
Antipsychotic drugs (APDs) are the first 
pharmacotherapeutic line of treatment for schizophrenia. 
They are also widely used for the treatment of bipolar 
disorder and other idiopathic psychotic disorders. The 
primary molecular targets of ADPs are the neurotransmitter 
receptors, dopamine receptors and their interaction 
are thought to be important for the “normalization” of 
neurotransmitter imbalances that are associated with 
specific symptoms and the acute manifestation of 
schizophrenia. Pimozide is a neuroleptic drug selectively 
blocks dopamine receptor D2 (DRD2) [1, 2], used 
to treat a number of mental/mood disorders (chronic 
schizophrenia), as well as other psychotic disorders, as 
it reduces dopamine activity and consequently decreases 
excitation, agitation, hypermobility, and abnormal 
conditions associated with excess energy [3, 4]. It has 
long been suggested that patients with schizophrenia have 
a reduced incidence of cancer compared to the general 
population [5, 6]. Many epidemiological studies have been 
conducted to investigate this possible link, but cancer risk 
in schizophrenic patients remains a controversial issue 
[7–9], although antipsychotic drugs have been suggested 
as possible mediators of this effect [5, 10, 11].
Ran GTPase (Ran), which belongs to the Ras 
superfamily of small GTPases, and the proteins which 
regulate GTP binding and hydrolysis have a well-defined 
role in nuclear transport [12, 13]. Ran itself is an abundant 
GTPase that is highly conserved in eukaryotic cells and 
has been implicated in many aspects of nuclear structure 
and function, cell cycle regulation, nuclear transport, and 
cell transformation [14, 15].
In this work, we identified Pimozide as a potential 
inhibitor of Ran using connectivity map analysis [16] 
of the breast cancer cell line MDA-MB-231, previously 
silenced by shRNA against the expression of the Ran gene. 
Pimozide was previously shown to inhibit proliferation of 
the human breast cancer-derived cell line MCF-7 in vitro 
by blocking estradiol-induced growth [17]. Pimozide has 
gained attention as an anti-cancer agent by acting as a 
STAT5 inhibitor in chronic myelogenous leukemia cells 
[18], as well as an inhibitor of STAT3 signaling pathway in 
hepatocellular carcinoma and suppressing cancer stem-like 
cell maintenance [19]. Previous work has demonstrated 
that Pimozide inhibited cell growth of Hepatocellular 
carcinoma (HCC) cells by disrupting the Wnt/β-catenin 
signaling pathway and reducing epithelial cell adhesion 
molecule (EpCAM) expression [20]. To explore the 
mechanisms involved in Pimozide inhibition of cancer 
and metastasis, we have analyzed the effect of Pimozide 
on breast cancer cell lines in vitro and breast cancer 
xenograft models in vivo. In this study, we demonstrate 
that Pimozide decreases Ran mRNA expression and 
reduces the expression of AKT and phosphorylation 
of VEGFR2 in breast cancer cell lines and in Human 
Umbilical Vein Endothelial Cells (HUVECs), leading to 
increased caspase-3 activation and apoptotic cell death. 
Pimozide also causes a reduction in cell proliferation, cell 
migration and invasion in vitro and of lung metastasis in 
vivo. Taken together, these results suggest that Pimozide 
may be of practical value in the management of human 
breast cancer, and could play a pivotal role in inhibiting 
cellular proliferation, migration, and metastasis.
RESULTS
Connectivity map (Map) analysis
The Java application sscMap, which was bundled 
with over 6000 reference gene expression profiles for 
over 1000 compounds as its core database, was queried 
to identify compounds that had significant connections 
to the expression of Ran in the human invasive breast 
cancer cell line MDA-MB-231, previously silenced with 
shRNA against the Ran gene. These 1000 distinct small 
molecule perturbagens, selected to represent a broad range 
of activities, include U.S. Food and Drug Administration 
(FDA)–approved drugs and nondrug bioactive ‘‘tool’’ 
compounds. The top candidate compounds that had 
significant connections to Ran expression are listed in 
Table 1. Highlighted in blue are drugs that are predicted 
to have inhibitory effects on the expression of Ran, whilst 
those in red are predicted to have an enhancing effect on 
Ran overexpression. As can be seen, Pimozide was highly 
ranked (P = 0.00001, z-score = -4.8028) compared to other 
drugs (Table 1).
Pimozide inhibits cancer cell growth in vitro and 
results in DNA damage
To investigate whether Pimozide exerts direct 
anti-proliferative and pro-apoptotic effects, and causes 
DNA damage, we treated human invasive breast cancer 
MDA-MB-231, normal breast MCF10A, and lung 
adenocarcinoma A549 cells with this drug at different 
doses for 24 or 48 hours, and cell morphology was 
observed after 24 hours (Figure 1A). Cell viability 
was assessed after treatment with different doses of 
Pimozide after 48 hours (Figure 1B). Whilst the survival 
of both cancer cell lines was significantly affected by 
Pimozide, MCF10A was relatively insensitive and 
showed little cell death (~5% cell death) even with 20 
μM Pimozide (which caused >90% cell death in MDA-
MB-231 and A549 cells). We next characterized the 
apoptotic cell death induced by Pimozide in MDA-
MB-231 and A549 cells by using several bona fide 
markers of apoptosis. Cell cycle analyses by flow 
cytometry showed that Pimozide treatment for 24 hours 
rendered an increase in the sub-G1 cell population, 
representing apoptotic cells (Figure 1C, 1D), and 
described in Supplementary Table 1, available online. 
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This apoptotic response, detected by the appearance 
of a sub-G1 population in cell cycle analysis, which 
is indicative of DNA degradation and DNA damage 
response (DDR) in MDA-MB-231 cells, was further 
supported by the internucleosomal DNA fragmentations 
(red arrow) and chromatin condensation (white arrow), 
and DNA blebbing (yellow arrow) detected after 48 h 
incubation with 7.5 μM Pimozide (Figure 1E). There 
was also evidence of double-strand DNA breaks 
(DSBs) measured by an increase of phosphorylated 
H2A histone family member X (γ-H2AX) expression 
after Pimozide treatment, to a greater extent than that 
observed with Doxorubicin and Paclitaxel (Figure 
1F). The normal breast cell line MCF10A showed no 
evidence of DDR at this dose or even at 15 μM of 
Pimozide (data not shown). In addition, we found that 
Pimozide induced caspase-3 activation, as assessed 
by cleavage of procaspase-3 into their respective p20 
active forms (Figure 1G), as well as by proteolysis 
of the caspase-3 substrate 116 kDa-poly(ADP-ribose) 
polymerase (PARP) into the 86-kDa cleaved form of 
PARP in MDA-MB-231 cells as assessed by Western 
blot (Figure 1H).
Pimozide reduced expression of Ran and AKT 
isoforms at both the mRNA and protein level 
and affected cMET and cMYC expression
Western blotting for Ran, AKT1 and AKT2 
isoforms revealed reduced protein expression after 
Pimozide treatment; Ran expression was reduced by 
45% after treatment with 5 μM Pimozide and by 87% 
after treatment with 10 μM Pimozide. AKT1 expression 
was almost completely abolished after treatment with 
5 μM Pimozide and AKT2 expression was reduced 
by 72% after treatment with 2.5 μM Pimozide. 
Table 1: Connectivity map analysis of human breast cancer MDA-MB-231 cells after Ran silencing using shRNA
Compound Replicates Set score p-value stdev zscore
Pimozide 4 -0.8084 0.00001 0.16833 -4.8028
SC-58125 4 -0.7283 0.00001 0.16583 -4.392
Pimethixene 3 -0.8298 0.00004 0.1952 -4.2507
Fluorocurarine 4 -0.6746 0.00004 0.16231 -4.1563
Chlorphenesin 4 -0.8019 0.00001 0.19792 -4.0514
Ouabain 4 -0.7897 0.0001 0.19517 -4.0463
Emetine 4 -0.8836 0.00002 0.22767 -3.8812
Vinpocetine 4 -0.8086 0.00002 0.2174 -3.7193
HNMPA-(AM)3 1 -0.9356 0.00002 0.28851 -3.2427
Oxamic acid 1 -0.9337 0.00002 0.28851 -3.2363
Tomelukast 1 0.93609 8.00E-05 0.28851 3.24454
Equilin 5 0.73566 2.00E-05 0.17639 4.17066
Promethazine 4 -0.7215 0.00004 0.18346 -3.9326
Etacrynic acid 3 -0.7908 0.00002 0.20202 -3.9146
Cortisone 3 -0.8615 0.00002 0.2284 -3.7716
Oxymetazoline 4 -0.8091 0.00001 0.2239 -3.6139
Sulfamethoxypyridazine 5 -0.8193 0.00002 0.2271 -3.6074
Dipyridamole 6 -0.734 0.00006 0.20596 -3.5638
Cotinine 6 -0.7913 0.00006 0.22281 -3.5512
Ronidazole 3 -0.8361 0.00008 0.25165 -3.3224
Lobeline 4 0.43885 8.00E-05 0.12488 3.51418
Docosahexaenoic acid ethyl ester 2 0.82579 0.00001 0.22997 3.59087
Alpha-yohimbine 3 0.75844 0.00012 0.20143 3.76532
Esculetin 3 0.81007 6.00E-05 0.21378 3.78931
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There was also a significant decrease (78%) in AKT 
phosphorylation after treatment for 24 hours with 
increasing concentrations of Pimozide up to 10 μM. 
(Student’s t test P < 0.05) (Figure 1I). In addition, the 
RNA expression of AKT isoforms (AKT1, AKT2 and 
AKT3) was measured (Figure 1J), revealing a significant 
reduction in the RNA expression of AKT1 (1.5 fold), 
AKT2 (9 fold), and AKT3 (4.76 fold) (Student’s t test P 
< 0.05) after treatment of MDA-MB-231 cells with 7.5 
μM Pimozide. There was also a significant reduction 
in the RNA expression of Ran (6.7 fold), c-Myc (2.5 
fold), and c-Met (9 fold) (Student’s t test P < 0.05) after 
24 hours of Pimozide treatment of MDA-MB-231 cells 
with the same dose of Pimozide (7.5 μM) (Figure 1K).
Pimozide inhibits the growth of invasive human 
breast cancer MDA-MB-231 xenografts in SCID 
mice
We tested the antitumor effects of Pimozide on the 
growth of human invasive breast cancer cell line MDA-
MB-231 xenografted tumors in vivo. Breast cancer cells 
Figure 1: Pimozide inhibits cell proliferation in a dose- and time-dependent manner by inducing cell cycle arrest and 
DNA double strand breaks (DSBs). (A) Phase contrast micrograph showing cell morphology of human breast cancer MDA-MB-231 
and lung cancer A549 cells treated with Pimozide at different doses (μM) for 24 hours. Scale bar 100 μm. (B) Viability of MDA-MB-231 
cancer cells, MCF10A normal breast cells, and A549 lung cancer cells after 48 hours treatment with Pimozide. (C) Cell cycle profiles. DNA 
content of fixed, propidium iodide-stained cells was analyzed by flow cytometry. MDA-MB-231 and A549 cells were incubated in the absence 
(control 0 μM of Pimozide with DMSO) or in the presence of Pimozide at different doses for 24 hours, and the percentage of cells in sub-G1 
(M1) (hypodiploidy), G0/G1 (M2), S (M3), and G2/M (M4) phases calculated using flow cytometry. The data gatings are indicated for each 
DNA histogram for M1, M2, M3 and M4. The percentage of cells with a DNA content less than G1 (sub-G1) is indicated in each histogram. 
The cell cycle profiles shown, with the sub-G1 population indicated, are representative of three experiments performed. (D) Cell cycle profile 
(Sub-G1) summarized using a histogram. MDA-MB-231 and A549 cells were treated with different doses of Pimozide for 24 hours, and the 
percentage of cells in the sub-G1 phase of the cell cycle (dead and dying cells) was quantitated by flow cytometry. Data shown are means ± SD of 
three independent experiments, **, P < 0.01, Student’s t-test. (E & F) DNA damage response (DDR) measured after treatment with Pimozide, 
Doxorubicin (Doxo) and Paclitaxel (Pac). (E) Representative fields of DAPI-stained DNA showing nuclear damage after 7.5 μM Pimozide 
treatment. Some nuclei show signs of dynamic DNA membrane blebbing (white arrow) and fragmentation after treatment for 48 hours, whilst 
other nuclei remained unchanged. There is also fragmented DNA outside (red arrow), and inside the nucleus (yellow arrow) suggesting 
chromatin condensation after treatment. Magnification 200x. Scale bar 10 μm. (F) Staining for histone γH2AX in MDA-MB-231 cells 
treated with 7.5 μM Pimozide or with 2.5 μM Doxorubicin or 100 nM Paclitaxel for 24 hours, images are representative of three experiments 
performed. Magnification 200x for DMSO and Pimozide treatment. Scale bar 10 μm. Magnification 400x. Scale bar 10 μm for Doxorubicin 
and Paclitaxel treatment. Pimozide reduced the protein and RNA expression of AKT and Ran, as well as RNA expression of cMYC and cMET. 
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were injected orthotopically into the mammary fat pat 
of SCID mice as described in Supplementary Figure 1A, 
available online. These cells were allowed to develop 
into mammary tumor xenografts, mice were divided into 
4 groups, Group-1 as nontreated control without tumors, 
Group-2 with nontreated tumors (NT), Group-3 with tumors 
treated the day after implantation with Pimozide 20 mg/kg 
(TE) and Group-4 with tumors that were treated with the 
same dose when the tumor was palpable (TL). The volume 
of tumors in the control group increased significantly 
between day 0 and day 14 (mean volume = 100 mm3), a 
representative mouse xenograft of each group (2, 3 and 4), 
is shown in Figure 2A. G3TE and G4TL mice are shown 
in Supplementary Figure 1B, available online. Beginning 
on day 14, mice in Group-4 were treated by i.p. injection 
of 20 mg/kg Pimozide for 5 days a week. Tumor volumes 
were reduced by 65% (P < 0.05) (Group-3) and by 60% (P 
< 0.05) (Group-4) (Figure 2B), although tumor occurrence 
in the treated groups were reduced by 55% (P < 0.05) 
(Group-3) and 61% (P < 0.05) (Group-4) (Figure 2B).
Tumor metastases were found only in the lung 
after a complete necropsy, and there were 94% (P < 
0.05) (Group-3) and 92% (P < 0.01) (Group-4) fewer 
metastases compared to the nontreated mice. The region 
of interests (ROI) finding for the same mice revealed 
a drastic reduction in light output between treated (7 
and 7.5 fold, Student’s t test P < 0.05) (Groups-3, 4, 
respectively), and untreated mice (Group-2) (Figure 
2B, left lower panel). Untreated tumor-bearing mice 
and treated mice (NT, TE and TL) were autopsied and 
the tumor sections were stained with Hematoxylin 
and Eosin. This showed the presence of nuclear 
fragmentations (red arrow) in tumors from TE mice and 
irregular pyknotic nuclei (white arrow) in tumors from 
TL mice, characteristic of cell death by apoptosis (Figure 
2C–2b, c). Magnification 200x. Scale bar 100 μm. A 
strong cell proliferation activity, as assessed by Ki67 
staining, was determined in the tumors from untreated 
mice (Figure 2C–2d), while cell proliferation was low in 
tumors from TE and TL mice (Figure 2C–2e,f)) as shown 
Figure 1: (Continued) Pimozide inhibits cell proliferation in a dose- and time-dependent manner by inducing cell cycle 
arrest and DNA double strand breaks (DSBs). (G) Western blotting analysis of Caspas-3 in MDA-MB-231 treated with Pimozide 
at different doses for 24 hours. β-Actin was used as a loading control. Data shown are representative of three experiments performed. (H) 
Western blotting analysis of PARP in MDA-MB-231 treated with Pimozide at different doses for 24 hours. β-Actin was used as a loading 
control. Data shown are representative of three experiments performed. (I) Western blotting analysis of Ran, AKT1, AKT2 and pAKT in 
MDA-MB-231 treated with Pimozide at different doses for 24 hours. β-Actin was used as a loading control. Data shown are representative 
of three experiments performed. (J) Relative mRNA expression of all AKT isoforms in MDA-MB-231 cells either untreated or treated with 
Pimozide 7.5 μM for 24 hours. Data shown are representative of three experiments performed. (K) Relative mRNA expression of Ran, 
c-MYC and c-MET in MDA-MB-231 cells treated with 7.5 μM Pimozide for 24 hours. Data shown are representative of three experiments 
performed.
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Figure 2: Pimozide reduces tumor burden, cell proliferation, and the number of lung metastases in a nude mice 
xenograft model system. (A) In vivo bioluminescence imaging system (IVIS) of MDA-MB-231-Luc (D3H2LN) xenografts in SCID 
mice. Ventral (upper left panels) images taken over time from representative mice (10 imaged). Upper right panels show the Region of 
Interest (ROI) in localized tumors from representative mice (10 imaged). Pseudo color scale bars were consistent for all imaged ventral 
views in order to show relative changes at metastatic sites over time, lower left panel images show metastatic foci in control mice (G2NT), 
and the lower right panel shows the ROI in different mice (red arrow). (B) Characterization of tumors in untreated (PBS) and treated 
(Pimozide) groups by plotting tumor volume (mm3), tumor occurrence (%), ROI (photons/sec) and lung metastatic foci numbers with 
significance values at autopsy. Data shown are means ± SD (Student’s t test *P <0.05, **P < 0.01). (C) Hematoxylin & eosin (H&E) staining 
of xenograft tumors in untreated (NT) (a), earlier treated (TE) (b) and late treated (TL) (c) mice. Magnification 200x. Scale bar 100 μm. 
Immunohistochemical staining for Ki67 (d,e,f). Magnification 200x. Scale bar 100 μm, cleaved caspase-3 (g,h,i). Magnification 200x. Scale 
bar 100 μm (g). Magnification 400x. Scale bar 50 μm (h, i) and Ran (j,k,l) in NT, TE and TL mice. Magnification 200x.Scale bar 100 μm 
(D) H&E staining of representative lung metastases from WT, NT, and TE mice. Ran immunostaining was assessed in wild type lung and 
lung metastases (NT and TE), magnification 200x. Scale bar 100 μm. (E & F) Immunohistochemical staining for AKT in MDA-MB-231 
xenograft tumors. (E) Immunohistochemical staining for AKT (Pan). Scale bar 100 μm. (F) AKT-isoforms (AKT1, AKT2) in untreated and 
treated mice breast xenografts tumors showing a representative result for 10 sections per group. Magnification 100x. Scale bar 100 μm.
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by a decreased stained cells for Ki67. There was also 
increased staining for cleaved-caspase-3 in tumors from 
both early- and late treated mice compared to tumors 
from untreated mice (Figure 2C–2g,h,i), together with 
an increase in apoptosis index in vivo as indicated by 
the red arrows. These results indicate that Pimozide 
treatment induces apoptosis in the MDA-MB-231 
tumors in vivo. Staining for Ran protein was reduced 
in tumors in the TE and TL treated groups (Figure 
2C–2j,k,l). Lung metastases were assessed at the end 
of experiment, and the highest number of lesions were 
found in the untreated mice (Figure 2D), with fewer 
lesions in early and late treated mice (Supplementary 
Figure 2A, 2B, available online) with very few focal 
metastases in the airway epithelium of TE mice (Figure 
2D). Carcinoma cells stained for Ran was checked using 
immunohistochemistry in metastatic lung foci, revealing 
a higher staining in lung metastases from nontreated 
mice (NT) compared to those from treated mice (TE) 
(Figure 2D).
Pimozide reduced expression of AKT1 and 
AKT2 in tumors of breast cancer xenograft 
tumors
To study the biological mechanisms underlying the 
growth inhibitory effects of Pimozide, the AKT signaling 
pathway, which plays a role during tumor development 
and angiogenesis, was assessed by examining the 
expression of two AKT isoforms (AKT1, AKT2) using 
immunohistochemistry. AKT (Pan) was absent from 
treated tumors but present in untreated tumors (Figure 2E), 
AKT1 expression was completely suppressed in treated 
tumors (TE and TL) compared to untreated tumors, 
whilst slight detection of AKT2 was observed in treated 
tumors, probably due to artefacts and staining techniques 
(Figure 2F).
Effect of pimozide on cell migration, invasion 
and metalloproteinase (MMP) expression
The consequence of 7.5 μM Pimozide treatment on 
the migration [21–23] of MDA-MB-231 and MCF7 breast 
cancer cell lines was investigated. Whilst the untreated 
cells had undergone collective migration into the empty 
space 24 hours post wounding, treated cells demonstrated 
a reduction in their abilities to migrate (Figure 3A) by 
30% (Student’s t test P < 0.05) in both MDA-MD-231 
and MCF7 breast cancer cells in the presence of Pimozide 
(Figure 3B).
The relative expression of MMP1 and MMP14 RNA 
was also decreased in MDA-MB-231 cells treated with 7.5 
μM Pimozide, by 3.3 and 2.5 fold, respectively, compared 
to untreated cells after 24 hours (Figure 3C), suggesting 
that Pimozide exerts a negative effect on MMP levels. 
We tested whether downregulation of Ran expression by 
three shRNAs against the Ran gene had a direct effect on 
metalloproteinase levels (Figure 3D). We selected three 
shRNAs against Ran (shRAN-1, shRAN-2, and shRAN-4) 
that efficiency reduced Ran protein expression by western 
blotting. Ran silencing reduced the expression of the 
active form of MMP2 by 70% (ShRNA1), 80% (shRNA2), 
and 56% (shRNA4) (Student’s t test P < 0.05). This was 
confirmed in vivo as the immunohistochemical analysis of 
tumors revealed a complete loss of MMP2 after Pimozide 
treatment (Figure 3E).
Pimozide inhibits migration related protein in 
MDA-MB-231 and A549 cancer cells
To provide further evidence of the migratory 
deficiencies after Pimozide treatment and possibly 
to provide clues about the molecular mechanisms 
involved, MDA-MB-231 and A549 cells were 
immunohistochemically stained for different markers 
related to cell motility, paxillin, myosin IIA, and Arp3 
(Figure 3F, 3G, 3H). Paxillin is a focal adhesion-
associated adaptor protein (FA) in a complex that 
acts as an interface between integrins and the actin 
cytoskeleton [24], myosin IIA is usually found in the 
lamella of motile cells and is mainly responsible for 
the contractile forces required during the organization 
of actin stress fibers [25], and Arp3 is a component of 
the Arp2/3 complex that promotes actin nucleation and 
polymerization and is mainly located at the leading 
edge and principally the lamellipodium of migratory 
cells [26]. Staining MDA-MB-231 cells for all these 
markers demonstrated their motile and invasive nature, 
with clear polarization and a well-defined leading 
edge (Figure 3F, 3G, 3H Paxillin, Myosin IIA, and 
Arp staining, respectively). Lamellipodia and filopodia 
structures were also clearly visible along with a few 
actin stress fibers throughout the cell bodies (Figure 
3F, 3G, 3H, Actin staining). Treatment of cancer cells 
with 7.5 μM Pimozide resulted in dramatic changes in 
the overall cytoskeletal architecture. Polarization and 
a defined leading edge was lost in most cancer cells, 
along with a significant reduction in the numbers of 
cellular protrusions, from an average of 65±10 (mean 
± SD) per cell in untreated cells to around 15±8 (mean 
± SD) in their treated counterparts (Student’s t test P < 
0.001) (Figure 3I). A very high concentration of actin 
stress fibers and punctate actin clusters could be seen in 
the body of the treated cells (Figure 3F, 3G, 3H, Actin 
staining). There were relatively few focal adhesion 
complexes in the control untreated cells (which is an 
indication of dynamic reorganization of these protein 
complexes and a sign of motility), incubating the 
cells with Pimozide resulted in an increased number 
of paxillin foci at localized regions of the cell body 
(Figure 3F, Paxillin staining). A549 cells treated with 
Pimozide likewise showed dramatic changes in cell 
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Figure 3: Pimozide suppresses the migration of breast cancer cells and reduces the expression of metalloproteinases 
(MMPs) in vitro and in vivo. (A) MDA-MB-231 and MCF7 cells were grown for 48 hours. Following wounding of the cell monolayers, 
cells were treated with 7.5 μM Pimozide, or control (DMSO) and their migration to close the wound measured over time. Time lapse images 
of MDA-MB-231 cells and MCF7 cells, immediately after wounding and after 24 hours. Scale bar 100 μm. (B) Quantification of wound 
closure presented as percentage of untreated control (DMSO) set at 100%, and treated cells representing the proportion of closed wounded 
area at 24 hours post wounding of MDA-MB-231 and MCF7 cultures. Data shown are means ± SE of three independent experiments, *, P 
< 0.05, Student’s t-test. (C) Relative mRNA expression of metalloproteinases MMP1 and MMP14 in MDA-MB-231 cells either untreated 
or treated with 7.5 μM Pimozide for 24 hours. Data shown are representative of three experiments performed. (D) Western blot showing 
protein levels of activated metalloproteinase MMP2 in cells treated with shScr, RAN-1, RAN-2, and RAN-4 shRNA for 24 hours. β-Actin 
was used as a loading control. Data shown are representative of three experiments performed. (E) Immunohistochemical staining for 
MMP2 in mouse tumor xenografts (NT & T). Magnification 200x. Scale bar 100 μm. Pimozide inhibits the migration of cells. Breast cancer 
MDA-MB-231 cells treated with 7.5 μM Pimozide or control (DMSO) were grown for 48 hours on fibronectin-coated coverslips prior to 
washing, fixing and immunostaining for either: (F) paxillin. Scale bar 50 μm, (G) myosin IIA, or (H) Arp 3. Scale bar 25 μm, together with 
staining for actin using rhodamine-phalloidin. Scale bar 100 μm. Data shown are means ± SD of three independent experiments, **, P < 
0.001, Student’s t-test. (I) Numbers of cellular protrusions summarized using a histogram, data shown are means ± SD of three independent 
experiments (n = 27), **, P < 0.001, Student’s t-test.
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morphology with fewer lamellipodia structures and 
lower Arp3 expression (data not shown). Microtubule 
stabilization and nuclei condensation in MDA-MB-231 
and A549 cells treated with either Pimozide (7.5 μM) or 
Paclitaxel (100 nM), were also studied (Supplementary 
Figure 3, available online), revealing a significant 
disorganization of their microtubule cytoskeleton 
as evidenced by extensive bundling throughout the 
cytoplasm and dramatic remodeling in both cell types.
Pimozide blocks the expression of epithelial 
to mesenchymal transition (EMT) markers in 
MDA-MB-231 cancer cells
RT-PCR-based analysis of two EMT markers 
(Vimentin and Zo-1) in MDA-MB-231 breast cancer 
cell lines treated with Pimozide for 24 hours revealed 
a significant decrease in the RNA expression of both 
markers (Figure 4A). A western blot for Snail, Vimentin, 
Figure 4: Pimozide induced epithelial mesenchymal transition (EMT) signaling pathways in MDA-MB-231 cells. (A) 
RT-PCR of the EMT mRNA markers Vimentin (Vim) and Zo-1 after 24 hours treatment with Pimozide at 7.5 μM and 10 μM, showing a 
reduction relative to mRNA for β-Actin. (B) Western blot of Snail, Vimentin and N-cadherin proteins after 24 hours of Pimozide treatment, 
β-Actin was used as a loading control. Data shown are representative of three experiments performed. (C) Relative level of mRNA for 
EMT markers in MDA-MB-231 cell lines treated with 7.5 μM Pimozide for 24 hours, showing a decrease in N-cadherin (Ncad), Vimentin 
(Vim), Snail, Slug and Twist compared to untreated control (DMSO). β-Actin was used as a loading control. Data shown are representative 
of three experiments performed. (D) Immunohistochemical staining for Vimentin in tumors from untreated mice (NT) and treated mice (T) 
with Pimozide (a representative of 10 sections per group). Magnification 200x. Scale bar 100 μm. Data shown are representative of three 
experiments performed.
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and N-cadherin proteins also revealed that the expression 
of each was reduced after treatment. After treatment with 
5 μM Pimozide Snail expression was reduced by 17% 
and Vimentin expression by 50%, whilst N-cadherin 
expression was reduced by 90% after treatment with 
only 2.5 μM Pimozide (Student’s t test P < 0.05) (Figure 
4B). The relative RNA expression of EMT markers 
was likewise reduced after Pimozide treatment at 7.5 
μM, by 2.5 fold (N-cadherin), 2.85 fold (Vimentin), 
1.42 fold (Snail), 6.66 fold (Slug), and 2.5 fold (Twist) 
(Figure 4C), while E-cadherin expression was unchanged 
during the treatment (data not shown). Similar results for 
Vimentin were obtained in the in vivo study as tumors 
from Pimozide treated mice showed a significant decrease 
in staining for Vimentin (Figure 4D). The expression of 
additional EMT markers - FGFR2b, FGFR2c, p63 (Pan), 
and ACTA2 – was studied in MDA-MB-231 cells either 
untreated or treated with Pimozide at 7.5 μM, which 
revealed a significant reduction in the RNA expression of 
p63 (Pan) (2 fold) and ACTA2 (4 fold) (Supplementary 
Figure 4A, available online).
Pimozide suppresses VEGF-induced cell 
migration and proliferation by reducing CD31 
expression and downregulating AKT signaling in 
HUVEC cells
To confirm an anti-angiogenesis effect of 
Pimozide in vivo, the expression of proteins involved 
in angiogenesis was assessed in treated and untreated 
tumors, and in vitro, using MDA-MB-231 and HUVEC 
cells. Immunohistochemical and immunofluorescence 
staining of tumor sections from Pimozide-treated mice 
revealed dramatically reduced staining for CD31 (Figure 
5A) and stained blood vessels by 78% (Student’s t test 
P < 0.05) (Figure 5B) compared to untreated mice. 
The relative RNA expression of VEGFR1 and VEGFR2 
was dramatically reduced, by 4.33 fold and 1.66 fold 
respectively, in fibroblast cells after Pimozide treatment 
at 7.5 μM (Supplementary Figure 4B, available online). 
Likewise, the promoter activity of the VEGFR2 gene 
in MDA-MB-231 and A549 cells was significantly 
reduced by Pimozide treatment between 5 and 20 μM 
after 24 hours, and was completely abolished with 
20 μM Pimozide (Supplementary Figure 5, available 
online). Immunoblotting of HUVEC cells treated 
with Pimozide for 24 hours (Figure 5C), revealed 
that Ran, AKT1, and AKT2 protein expression had 
reduced by 73%, 97%, and 95% respectively, after 
treatment with 5 μM Pimozide (Student’s t test P < 
0.05). Phosphorylation of AKT and VEGFR2 was 
also dramatically reduced, although VEGFR2 protein 
expression increased (Figure 5C). Moreover, Pimozide 
exerted anti-proliferative effects on HUVEC cells with 
an increased apoptosis index measured as the fraction 
of cells in the sub-G1 part of the cell cycle by flow 
cytometry after treatment for 24 hours (Figure 5D), and 
there was a significant (20%) increase in cell death with 
only 2.5 μM Pimozide.
Pimozide prevents TGFβ-induced myofibroblast 
cell differentiation by increasing apoptosis and 
reducing αSMA formation
Since myofibroblasts play an important role in 
metastasis by increasing the invasion and migration of 
cancer cells [27, 28], we further studied the effects of 
Pimozide treatment on myofibroblast cell differentiation, 
proliferation, and apoptosis. To address this process in 
vitro, we stimulated myofibroblasts with TGF-β1 (2.5 ng/
mL). The expression of α-SMA protein increased after 24 
hours and was highly elevated after 72 hours (Figure 6A), 
however treatment with Pimozide at 7.5 μM prevented 
fibroblast to myofibroblast differentiation by increasing 
apoptosis (Figure 6A, white arrow) as confirmed by cell 
cycle analysis (flow cytometry) with increasing apoptosis 
(Sub-G1) at increasing concentrations of Pimozide after 
24 hours (Figure 6B). In vitro treatment of fibroblastic 
cells with increasing concentrations of Pimozide also 
increased apoptosis (Figure 6C). We also studied the 
effect of Pimozide on tumor associated myofibroblasts 
through immunohistochemical staining for αSMA in 
mouse tumors. This protein was completely depleted in 
breast tumors in mice treated with Pimozide compared to 
those in untreated mice (Figure 6D), and the treated mice 
also had fewer lung metastases (Supplementary Figure 2B, 
available online).
High level of VEGFR2 and Ran tumor 
expression is correlated with shorter survival 
time of breast cancer patients
Tumors were stratified according to mRNA 
expression of Ran and VEGFR2. A high level of expression 
for Ran and VEGFR2 was associated with shorter patient 
survival time (Wald test, P < 0.001; Figure 7A, 7B), 
although this relationship was weaker in patients with 
low Ran and VEGFR2 expression (Wald test, p= 0.031; 
Figure 7C, p= 0.0021; Figure 7D).
Association between VEGFR2 and Ran mRNA 
expression in human breast cancer
The mRNA levels for Ran and VEGFR2 from six 
independent breast datasets were analyzed, revealing a 
statistically significant positive correlation between the 
mRNA levels of these two genes in all six individual 
datasets (Pearson’s correlation, P < 0.001 (Figure 7, 
7E-7J)). When the six datasets were combined (n = 1334) 
(Figure 7K), the positive association between Ran and 
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Figure 5: Pimozide inhibits the expression of angiogenesis related markers in vivo and induced apoptosis in HUVEC 
endothelial cells. (A) Immunohistochemical and immunofluorescent detection of the endothelial cell marker CD31 in MDA-MB-231 
tumors from untreated mice and mice treated with Pimozide (representative of 10 sections per group). Scale bar 100 μm. (B) Histogram 
showing numbers of blood vessels in untreated and Pimozide treated tumor sections, Pimozide-treated tumors exhibited a ~three-fold 
reduction in CD31 staining, Student’s t-test *P < 0.05 vs control. (C) Western blotting of AKT1, AKT2, pAKT, VEGFR2 and pVEGFR2 
proteins in HUVEC cells treated with Pimozide for 24 hours. β-Actin was used as a loading control. Data shown are representative of three 
experiments performed. (D) DNA ploidy analysis by flow cytometry of HUVEC cells treated for 24 hours with Pimozide. Untreated control 
cells were run in parallel. Apoptosis was determined in flow cytometry by the percentage of hypodiploid (sub-G1) cells following cell cycle 
analysis. The percentage of cells with a DNA content less than G1 (sub-G1) is indicated in each histogram. The cell cycle profiles shown, 
with the sub-G1 population indicated, are representative of three experiments performed.
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VEGFR2 mRNA levels was highly significant (Pearson’s 
correlation 0.67, P < 0.001). These results strongly 
demonstrate the positive association between VEGFR2 
and Ran expression in patient specimens.
DISCUSSION
Several epidemiological studies have noted a 
lower rate of lung cancer among schizophrenic patients 
compared to the general population, even though these 
patients are more likely to smoke. Likewise, clinical data 
indicates that the use of medication for schizophrenia 
lowers the relative risk of cancer [5, 6, 10]. It has also 
been shown that the neuroleptic agents Pimozide and 
Thioridazine inhibit cancer growth in culture [17], either 
by targeting STAT3/STAT5 signaling pathways [18, 19] 
or by disrupting the Wnt/β-catenin signaling pathway 
[20] and more recently another group [29] reported that 
Pimozide kills lung, breast, and brain cancer cells in vitro 
[30], In this study we have attempted to elucidate further 
the mechanism underlying these clinical observations and 
identify a novel biological function for Pimozide.
This study is the first to report that an FDA-
approved neuroleptic drug, Pimozide, which is already 
in clinical use, has multiple anticancer effects, since it 
inhibits cell proliferation, and has an anti-angiogenic 
Figure 6: Pimozide suppresses fibroblast differentiation, reduces cell proliferation and increases apoptosis. (A) 
Immunofluorescent detection of α-SMA/SMAD2-3 in untreated (DMSO) and treated fibroblasts with 7.5 μM Pimozide for 24 hours. The 
nuclei are stained blue (DAPI), smooth muscle in differentiated fibroblasts green, and SMAD2-3 red (nuclear staining). Primary human 
fibroblasts were pre-treated with 7.5 μM Pimozide, 1 hour prior to TGFβ1 treatment. Fibroblasts were stimulated to differentiate by addition 
of TGFβ1 for 72 hours. In vehicle control (DMSO)-treated cultures fibroblast differentiation was observed by the formation of polymerized 
smooth muscle actin filaments. However, in the presence of Pimozide, TGFβ1 was unable to promote the formation of these filaments. 
In Pimozide treated cells, SMAD2-3 is nuclear both in the control and TGFβ1-treated cultures. Exposure TGFβ1 treated fibroblasts to 
Pimozide resulted in increased apoptosis which is apparent from the increased number of condensed nuclei (white arrows). Scale bar 100 
μm. (B) Cell cycle profile (Sub-G1) summarized using a histogram. Primary fibroblast cells were treated with different doses of Pimozide 
for 24 hours, and the percentage of cells in the sub-G1 phase of the cell cycle (dead and dying cells) was quantitated by flow cytometry. 
Data shown are means ± SD of three independent experiments, **,P < 0.01, Student’s t-test. (C) Phase contrast micrograph showing the 
morphology of fibroblast treated with Pimozide at different doses for 48 hours. Scale bar 100 μm. (D) Immunohistochemical staining for 
α-SMA in MDA-MB-231 tumors from untreated mice (PBS) and treated mice (representative of 10 sections per group). Magnification 
100x. Scale bar 100 μm.
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Figure 7: High level of Ran and VEGFR2 is correlated with shorter survival time of breast cancer patients. (A-D) 
Kaplan-Meier plot of survival of breast cancer patients from five microarray datasets available in GEO database for Ran and VEGFR2 
mRNA. (A) Ran-high group stratified into high and low VEGFR2. The two curves were significantly different (Wald test χ2 = 67.03, 1 df, 
P < 0.001 (P = 2.2e-16)). (B) VEGFR2-high group stratified into Ran high and low. The curves differed with a high degree of significance 
(χ2 = 138.61, 1 df, P < 0.001 (P = 1e-16)). (C) Ran-low level group stratified into VEGFR2 high and low. The high group for VEGFR2 
showed a significantly lower patient survival time (χ2 = 4.64, 1 df, P = 0.031). (D) VEGFR2-low group stratified into high and low Ran. The 
curves differed with a high degree of significance (χ2 = 9.5, 1 df, P = 0.0021). Only datasets that included at least 150 patients were included, 
and the correlations between relative mRNA levels of VEGFR2 and Ran in each dataset were compared using Pearson’s correlation analysis 
(E–J). In all the datasets tested in this study GSE2034 (n = 286) (E), GSE1456 (n = 159) (F), GSE12276 (n = 204) (G), GSE11121 (n = 200) 
(H), GSE7390 (n = 198) (I), and GSE4922 (n = 289) (J), the relative mRNA levels of VEGFR2 and Ran were significantly positively 
correlated (Pearson’s correlation; P < 0.05). (K)Association of mRNA levels of VEGFR2 and Ran in GSE-6sets-combined breast cancer 
patients. The relative mRNA levels of VEGFR2 and Ran were significantly positively correlated (Pearson’s correlation; P < 0.05).
Oncotarget34902www.oncotarget.com
and anti-metastatic activity. We found that Pimozide 
inhibited breast and lung cancer cell proliferation and 
sphere formation (data not shown) primarily by inducing 
apoptosis. These results are in agreement with other 
studies that showed an inhibitory effect of Pimozide on 
cell growth in breast cancer [17]. Pimozide also had a 
genotoxic effect on DNA by promoting DNA double-
strand breaks measured by an increase of phosphorylation 
of histone H2AX (λ-H2AX), which is a marker of genomic 
instability [31], to a greater degree than the other FDA-
approved chemotherapeutic drugs tested, Doxorubicin and 
Paclitaxel.
It was also demonstrated for the first time in this 
study that Pimozide acts as a potent anti-angiogenic 
modulator through the inhibition of the AKT and VEGF 
signaling pathways. Interestingly, the data showed 
that Pimozide affected the AKT signaling pathway by 
downregulation of phospho-AKT (Ser-473) and AKT 
gene expression. Previous studies have demonstrated that 
the effects of Pimozide on neurologic diseases are via 
antagonism of DRD2 [32], indeed, DRD2 is expressed 
in various cancer types [33, 34] and has been involved 
in regulating Wnt and AKT signaling [35] therefore, we 
postulate based on the data herein that the reduction of 
AKT signaling and AKT gene expression by Pimozide 
may result from inhibition of DRD2 receptor. This has 
been implicated in previous study which showed that 
downregulation of DRD2 whether through transient 
knockdown of the receptor or pharmacological antagonism 
can have cytotoxic effects towards cancer cells [36]. 
On the other hand, we have shown a potent anticancer 
effect of Pimozide, this may be attributed at least in part 
to Pimozide ability to engage other pathways that are 
not directly related to DRD2 antagonism. We observed 
decreased expression of Ran at mRNA and protein level 
in vitro and in an in vivo MDA-MB-231 xenograft model. 
It has been reported that typical and atypical antipsychotic 
drugs [37–40] can alter transcription particularly through 
altered binding of Fos and Jun family of transcription 
factors (TF) to their cognate AP-1 DNA binding site. We 
speculate that Ran expression may be directly regulated 
via these mechanisms or potentially via Pimozide driving 
expression of an unknown factor which can then decrease 
Ran mRNA expression and be responsible for decreased 
levels of Ran protein expression. However, further studies 
are needed to test these hypotheses.
The phosphorylation of VEGFR-2 plays an 
important role in promoting VEGF-induced tumor 
angiogenesis [41, 42], and we found that Pimozide also 
suppresses VEGF-induced HUVEC proliferation. It is well 
established that VEGF plays an important role in tumor 
angiogenesis by activating the proliferation and migration 
of endothelial cells during micro-vessel formation [43], 
and correspondingly we found that VEGF probably 
contributes to the growth of breast tumors both directly 
through its action on cancer cells and through its effect 
on angiogenesis as shown by a drastic reduction in blood 
vessel formation.
In cancer, endothelial cells play a pivotal role 
in regulating various aspects of vascular biology and 
pathology. Although VEGFR-1 and VEGFR-2 are 
structurally similar, they have distinct functions during 
angiogenesis. VEGFR-2 plays a vital role in activating the 
major downstream components responsible for cell growth, 
endothelial cell invasion, migration, differentiation, and 
embryonic angiogenesis [44, 45], whilst VEGFR-1 has no 
role in the proliferation and migration of endothelial cells 
[46]. Promoter analysis of the VEGFR-2 gene showed 
a clear dose-and time dependent inhibitory response to 
Pimozide (Supplementary Figure 5, available online), 
indicating that this and other neuroleptic agents could 
exert antitumor effects through disrupting the vasculature 
in addition to promoting apoptosis in the tumor cells 
themselves.
The production of MMPs by tumor cells promotes 
cellular migration and invasion through degradation of 
the extracellular matrix. The results of the present study 
show that Pimozide can downregulate MMPs-1 -2, and 
-14 (Figure 3C, 3E). MMPs are zinc dependent enzymes 
reported to be involved in the initial stages of invasion and 
metastasis of various tumor cells [47]. Activation of MMPs 
has been observed in a variety of metastatic tumor tissues, 
and hence numerous anticancer drug formulations focus 
primarily on attenuating the expression of these enzymes. 
Inhibition of MMP expression and activity is considered 
to be an early target for preventing cancer metastasis 
[48]. Our results demonstrated that an anticancer effect of 
Pimozide is associated with decreased MMP expression 
in vitro and in vivo (Figure 3C, 3E). This concurs with 
the finding that Ran silencing also downregulated MMP2 
in MDA-MB-231 cells (Figure 3D). Hence Pimozide 
may prevent the migration of cancer cells at least in part 
through the down-regulation of MMP2 (Figure 3A, 3B).
We also found that Pimozide significantly inhibited 
MDA-MB-231 cell growth, migration, invasion and 
tumorigenicity in vivo and these effects were associated 
with suppression of EMT, a process involving the 
breakdown of cell-cell junctions and loss of epithelial 
polarity [49–51]. In our study, the expression of 
N-cadherin and Vimentin, and the transcription factors 
Twist, Slug, and Snail [52, 53] were reduced in vitro, 
and Vimentin expression was also reduced in vivo after 
Pimozide treatment (Figure 4D). Interestingly E-cadherin 
was unchanged during treatment suggesting that reversal 
of EMT was only partial or incomplete.
The present study also investigated the modulation of 
motility and expression of the FA protein, paxillin, and the 
cytoskeletal proteins myosin IIA and Arp3 after Pimozide 
treatment. These studies showed that Pimozide inhibits 
motility of breast and lung cancer cells in vitro and that 
there was a corresponding upregulation of these proteins 
and a change in the spatial relationship between FAs and 
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Figure 8: Summary figure of proposed pimozide mechanisms. (A) Hypothetical representation of Pimozide signaling pathways 
involved in cell proliferation, survival, metastasis, and angiogenesis. (B) Schematic representation of Pimozide effects on tumor cells and 
the tumor microenvironment, including fibroblasts and HUVEC cells.
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actin filaments. There were also pronounced changes in the 
overall cytoskeletal architecture of these cells including a 
dramatic reduction in the number of cellular protrusions and 
an increase of actin stress fibers in response to Pimozide 
treatment suggesting a possible mechanism of action that 
depends on cytoskeletal distribution.
An anti-proliferative and anti-metastatic role 
for Pimozide is further supported by the finding that 
Pimozide suppresses the differentiation of fibroblasts to 
myofibroblasts. The latter are a component of the tumor 
microenvironment and help maintain tumor growth and 
invasion [54, 55]. This in turn points to an additional 
mechanism by which Pimozide can inhibit breast cancer 
tumor invasion. Myofibroblasts tend to promote tumor 
growth, especially in breast cancer, and hence could 
represent an additional therapeutic target.
Collectively this study provides strong evidence for 
multiple molecular mechanisms (Figure 8A, 8B) through 
which Pimozide exerts anti-tumor activity in breast cancer 
cells and therefore could be a useful agent for treatment 
in the future.
MATERIALS AND METHODS
Cell culture
The MDA-MB-231 and MCF-7 breast cancer cell 
lines, A549 lung cancer cell line and viral packaging cell lines 
293T (HEK) were obtained from the American Type Culture 
Collection (ATCC), Manassas, VA, US and maintained in 
culture medium (DMEM) containing 10% (v/v) fetal bovine 
serum (FBS) and 2 mM L-glutamine. MDA-MB-231-Luc 
(D3H2LN), was purchased from Cell Biolabs, INC (Cell 
Biolabs, San Diego, CA, USA). Human Umbilical Vein 
Endothelial Cells (HUVECs) were kindly donated by Dr. 
Andriana Margariti (Center of Experimental Medicine, QUB, 
Belfast, UK) and cultured with EGM-2 medium (Cambrex, 
Corporate, NJ, US). The Ras-transformed MCF10A 
derivative MCF10AT cell line (from Karmanos Cancer 
Centre, Detroit, MI, USA) was maintained in DMEM/F-12 
medium containing 5% horse serum (v/v), 10 μg/ml insulin, 
20 ng/ml epidermal growth factor (EGF), 100 ng/ml cholera 
toxin and 0.5 μg/ml hydrocortisone. Primary Human Foreskin 
Fibroblasts, purchased from Cascade Biologics - Thermo 
Fisher Scientific, Paisley, UK, were cultured in 1:1 (v/v) 
Dulbecco’s modified Eagle’s medium (DMEM)/Ham’s F-12 
medium containing 10% (v/v) FBS and antibiotics (100 units 
of penicillin, 100 μg of streptomycin, 0.25 μg of amphotericin 
B, and 50 μg of gentamicin per ml). Human recombinant 
TGF-β1 (R&D, Minneapolis, MN) at 2.5 ng/ml with and 
without Pimozide at 7.5 μM, was used to treat human 
fibroblast on the next day. All cell lines were previously 
tested for mycoplasma contamination using MycoProbe 
Mycoplamsma Detection Kit (R&D systems, Abingdon, 
UK). Pimozide (Orap), Doxorubicin and Paclitaxel was 
purchased from Sigma Aldrich, dissolved and stored as 
indicated by the manufacturer’s, DMSO was purchased from 
Sigma Aldrich to dissolve all drugs and used as control.
Transfection
Transfection was performed using GeneJuice® 
(Promega, Southampton, UK) according to the 
manufacturer’s instructions. shScr, shRAN-1, shRAN-2 
and shRAN-4, (Sigma-Aldrich, Dorset, UK) were used 
for Ran knockdown by Lentiviral infection as previously 
described [56].
Luciferase reporter-gene assay
In vitro luciferase activity was performed as 
reported previously [57]. In brief, cells at 80 to 85% 
confluency were co-transfected with promoter Renilla 
luciferase plasmids with Renilla luciferase reporter 
(Promega, Hampshire, UK) for 24 hours. After lysis with 
Radio Immunoprecipitation Assay (RIPA) buffer, lysates 
were cleared by centrifugation for 15 minutes at 14000 
rpm and the cell extracts were incubated with luciferase 
substrate for 30 minutes at room temperature, as indicated 
by the manufacture, then a 5 μl aliquot of each sample was 
quantified in a MicroLumat Plus LB96V luminometer. 
The ratio of luciferase fluorescence was normalized for 
the Renilla luciferase fluorescence to correct for variation 
within transfections. The results were the mean ± SD of 
the expression of three independent experiments.
Real-Time polymerase chain reaction
Total RNA was isolated using the TRIZol reagent 
(Invitrogen) and reverse transcription was performed 
using SuperScript™ III first strand synthesis system 
(Invitrogen), according to the manufacturer’s instructions. 
The concentration of purified RNA was determined by the 
Agilent 2100 bioanalyzer using RNA 6000 NanoChips 
(Agilent, Waldbronn, Germany). The primers used for 
gene expression were purchased from R&D Systems 
(Supplementary Table 2, available online). As an internal 
standard, the RPLO (50S ribosomal protein L15) gene was 
chosen as a house-keeping gene. qRT-PCR was performed 
using the QuantiTect SYBR Green RT-PCR kit (Qiagen, 
Hilden, Germany) on a DNA Engine Opticon (Bio-Rad, 
Loanhead, UK). All reactions were performed with 500 
ng of total RNA in a volume of 25 μl. Thermal cycling 
conditions were 30 minutes at 50°C, 15 minutes at 95°C, 
followed by 35 cycles of 30 seconds at 95°C, 30 seconds at 
60°C, and 30 seconds at 72°C and finished with a melting 
curve. The expression level of each gene was quantified 
using the 2-ΔΔCt method [58].
Western blot analysis
Western blotting was performed as previously 
described [59]. Briefly, cells were lysed in RIPA buffer 
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containing protease inhibitors. The samples were separated 
by SDS-PAGE and transferred onto a nitrocellulose 
membrane (Millipore, Watford, UK). The membranes 
were blocked with 5% (v/v) nonfat dried milk in PBS 
and subsequently incubated with primary antibodies 
anti-active caspas-3 (1:1000) from BD Pharmingen, anti-
PARP (1:1000) from Cell Signaling, anti-Ran (1:2000), 
anti-MMP2 (1:100) from Millipore, anti-Snail (1:1000), 
anti-Vimentin (1:1000), anti-N-cadherin (1:1000), anti-
E-cadherin (1:1000), anti-AKT1 (1:1000), anti-AKT2 
(1:1000), anti-pAKT (1:2000), anti-VEGFR2 (1:1000) and 
anti-pVEGFR2 (1:1000) from Cell Signaling, overnight 
at 4º C. Bound antibodies were detected by horseradish 
peroxidases-conjugated secondary antibodies at 1:10000 
at RT for 1 hour with enhanced chemiluminescence 
(Amersham Pharmacia Biotech, Chalfont, UK) for 
detection. Densitometry on scanned immunoblot images 
was performed using the ImageJ software.
Apoptosis assays
Quantification of apoptotic cells was determined by 
flow cytometry as the percentage of cells in the sub-G1 
region (hypodiploidy) of a cell cycle analysis as previously 
described [60]. Cell cycle profiles were generated using 
manually drawn gates with Cyflogic software.
MTT cell proliferation and survival assay
Cells were seeded at a cell density of 3000 cells/
well in a 96-well plate in triplicates and allowed to grow 
for 24 hours and before Pimozide at different doses was 
added. The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) dye uptake method was 
used as previously described [61] to assess cell survival 
24, 48 and 72 hours post-treatment.
Boyden chamber migration and invasion assays
Migration and invasion assays were performed as 
previously described [62]. Briefly, 5000 and 50000 cells 
in serum-free media were seeded into the upper chamber 
(Millipore) on top of the membrane with or without a 
Matrigel coating, respectively, for migration and invasion 
assays. The cells were allowed to migrate or invade 
towards the bottom layer with 10 ng/ml hepatocyte growth 
factor (HGF) as chemoattractant for 24 hours. Cells in 
the bottom of the membrane were fixed and stained with 
crystal violet.
Cell adhesion assay
For the cell adhesion assay, 4000 cells suspended 
in serum-free media with or without 10 ng/ml HGF were 
seeded per well in a 96-well plate coated with fibronectin 
and the cells were allowed to settle for 30 minutes. Non-
adherent cells were then removed by washing 4 times 
with PBS. Adherent cells were fixed and stained with 
crystal violet. The excess dye was washed away, and the 
retained dye was extracted. The absorbance at 595nm was 
measured in a microplate reader.
Xenograft mouse models
Animal procedures in this study complied with 
UK Animal Use in Research Guideline (UK Directive) 
and the European Union (European Directive 2010/63/
EU) guidelines on animal Experimentation for the 
Protection and Humane use of Laboratory Animals, and 
were conducted at an accredited Animal Experimentation 
Facility (MBC, Queen’s University, UK). Procedures 
were approved by the Ethics Committee at Queen’s 
University. Female C57/BL6 nude mice (8-weeks 
old), were kept and handled according to Institutional 
Guidelines, complying with UK legislation under 
12/12 hours light/dark cycle at a temperature of 22°C, 
and received a standard diet and acidified water ad 
libitum. MDA-MB-231-Luc cells (2 × 106) were injected 
subcutaneously in 100 μl phosphate-buffered saline 
together with 100 μl Matrigel (Becton Dickinson) 
into one mammary fat pad of each mouse. Mice were 
randomly assigned to cohorts of ten mice each, and 
were grouped in four groups, Group-1 (G1) without 
cell implantation and without treatment; Group-2 mice 
received cells and were not treated with Pimozide 
(G2NT); Group-3 mice were implanted with cells and 
treated a day earlier prior to implantation (G3TE); 
Group-4 mice were injected with cells and treated late 
when tumors were palpable (G4TL), G3TE & G4TL 
mice received an i.p. injection of 20 mg/kg Pimozide or 
the same volume of vehicle (PBS) as the G2NT animals. 
The shortest and longest diameter of the tumor were 
measured with calipers at the indicated time intervals, 
and tumor volume (mm3) was calculated using the 
following standard formula: (the shortest diameter)2 × 
(the longest diameter) × 0.5. Animal body weight and any 
sign of morbidity were monitored. Drug treatment lasted 
4 weeks. Animals were killed 24 hours after the last drug 
administration according Schedule 1 killing procedures, 
and then tumors were carefully removed, weighed, and 
analyzed. A total necropsy involving tumors and distinct 
organs was carried out.
Histochemical analysis
Tumor tissue samples were fixed in 4% (w/v) 
buffered paraformaldehyde and embedded in paraffin. 
Wax tissue sections (4-5 μm) were deparaffinized 
and hydrated in graded ethanol and distilled water. 
Endogenous peroxidase activity was blocked using 
methanol and 3% H2O2 for 30 minutes as previously 
described [59]. Histological sections were counterstained 
Oncotarget34906www.oncotarget.com
with hematoxylin and eosin (H&E), others were then 
incubated at 4°C with different antibodies: rabbit anti-
human Ki67 monoclonal antibody (clone SP6) (1:1000 
dilution, Abcam), anti-active human cleaved-caspase-3 
(1:200 dilution for IHC & 1:100 for IF, Cell Signaling) 
rabbit polyclonal antibody that specifically recognized the 
active ~20-kDa subunit (Cell Signaling), anti-human Ran 
(1:1000, Millipore), anti-human MMP2 (1:100 dilution, 
Millipore), anti-AKT (Pan) (1:300, Cell Signaling), anti-
AKT1, anti-AKT2, anti-phospho-AKT (1:1000, Cell 
Signaling), anti-human CD31 (1:50 for IHC and 1:20 for 
IF, Abcam) and anti-α-smooth muscle actin (α-SMA) (1:50 
for IHC and 1:100 for IF, Abcam). After washing with 
PBS, sections were incubated with biotinylated anti-rabbit 
IgG antibody (BD Pharmingen) for 60 minutes at room 
temperature and washed with PBS. Then, sections were 
incubated with streptavidin horseradish-peroxidase (Vector 
Laboratories) for 60 minutes in a moist chamber, washed 
with PBS, and sites of peroxidase activity were visualized 
using 3,3′-diaminobenzidine tetrahydrochloride solution 
(DAB). Sections were subsequently counterstained with 
hematoxylin Mayer’s & Eosin (Sigma). Staining was 
analyzed with a Nikon Eclipse 400® microscope and 
Metamorph® software (Molecular Devices Corporation).
Immunofluorescence staining
Human breast and lung cancer cell lines MDA-
MB-231, MCF7 and A549 were seeded onto fibronectin-
coated (2.5 μg/cm2) glass coverslips (15000 cells/coverslip) 
in a 24-well plate. Following 48 hours incubation, cells 
were stained in order to analyse cytoskeletal organization 
as previously described [24], they were first washed once 
in cytoskeletal buffer (CB: 150 mM NaCl, 5 mM MgCl2, 
5 mM EGTA, 5 mM glucose, 10 mM 2-(N-morpholino) 
ethane-sulfonic acid, (pH 6.1) prior to fixation at 37°C for 
20 minutes in CB buffer with 3.7% (w/v) paraformaldehyde. 
Cells were then further washed in CB buffer before being 
permeabilized with 5% (v/v) Triton-X100 in CB buffer for 
2 minutes and blocked with 5% (v/v) goat serum in CB 
buffer for 60 minutes. Samples were incubated with primary 
antibodies against either myosin IIA (Covance), paxillin 
(Abcam) or Arp3 (Abcam) at a dilution of 1:1000, 1:100 
and 1:200, respectively in blocking solution, 5% (v/v) goat 
serum in CB buffer for 45 minutes at room temperature. 
After washing three times with blocking solution, cells 
were incubated with their corresponding secondary 
antibodies (anti-rabbit and anti-mouse antibodies labelled 
with FITC) in blocking solution for 45 minutes at room 
temperature. For actin staining, rhodamine phalloidin was 
also added with secondary antibodies at a concentration 
of 0.6 μM. Staining for γH2AX, αSMA, SMAD2/3 and 
TGFβ1, was carried out on MDA-MB-231 cells grown 
in glass coverslips with and without treatment. Cells were 
incubated with primary antibodies anti-γ-H2A.X (phospho 
S139) antibody [9F3] (1:1000, Abcam), anti-αSMA (1:100, 
Abcam), anti-Smad2 and anti-Smad3 (1:1000, Abcam) and 
anti-TGFβ1 antibody (1:100, Abcam), respectively. Cells 
were stained with DAPI to visualise the nucleus. After 
washing three times with blocking solution, cells were 
incubated with their corresponding secondary antibodies 
(anti-rabbit and anti-mouse antibodies labelled with FITC). 
After washing with blocking solution, coverslips were 
rinsed with water and mounted in vectashield antifade 
mounting medium (Vector Laboratories), and viewed using 
a confocal microscope (TCS SP5 II Confocal, Leica) using 
a HCX PL APO 63x/1.4–0.6 oilCS objective at 20% argon 
laser intensity.
Motility wound healing assay
The wound closure assay was performed to 
determine changes in cellular motility. For this assay, either 
1×105 MCF7 or 6×104 MDA-MB-231 cells were seeded 
into each well of a 24-well tissue culture plate and left to 
grow for 48 hours to reach 90-95% confluency. Confluent 
monolayers were scratched with a sterile pipette tip prior 
to addition of 7.5 μM Pimozide in normal medium for the 
treated cells. Wound closure was monitored by collecting 
digitalized images using the Cell-IQ automated image 
capture system (Chip-Man Technologies) on preselected 
fields using phase contrast microscopy. Analysis of the 
collected data was performed using the Cell-IQ Analyser 
Software, to generate percentage of wound closure over 
time. Quantification of the closed area after 24 hours was 
used to generate data for this assay and normalized as a 
percentage of the closed area in the untreated control.
Connectivity mapping analysis
Gene expression connectivity mapping is an 
advanced bioinformatics technique to establish the 
connections among genes, drugs, and diseases via gene 
expression profile similarities. The statistically significant 
connections map (sscMap) framework [63–65] was 
used to search for small molecule compounds with 
potential to suppress the expression of Ran. Briefly, 
the reference gene expression profiles included in the 
sscMap core database were based on Affymetrix HG-
U133A microarray platform, and Affymetrix Probset IDs 
were used as gene identifiers in those profiles. To make 
connections between Ran expression and candidate small 
molecules, gene symbols including Ran were mapped 
to the Affymetrix Probset IDs using the corresponding 
Affymetrix annotation file. The connections between Ran 
expression and the reference profiles of each compound 
were assessed with the scoring and statistical testing 
procedures, as previously described [64].
Statistical analysis
Data are presented as the mean ± standard 
deviation (SD) or ± standard error (SE). The Student’s 
t-test and one-way ANOVA were used to assess the 
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significance of independent experiments. Survival 
analysis was performed using Kaplan-Meier plots and 
significance of differences were tested using the Wald 
test. A p-value < 0.05 was considered significant in all 
statistical analyses. Differences in expression levels 
between groups/samples in human specimens were 
analyzed using the χ2, Fisher exact, or Mann-Whitney U 
tests, and where applicable, Pearson’s correlation, using 
SPSS 19.0 software (IBM, Armonk, NY).
Analysis of breast cancer microarray data
Five breast cancer datasets [GSE1456 [66], 
GSE2034 [67], GSE4922 [68], GSE7390 [69], 
GSE12276 [70]], obtained from Gene Expression 
Omnibus (GEO) (https://www.ncbi.nlm.nih.gov/geo/), 
each consisting of more than 150 patients with their 
corresponding microarray gene expression data and 
survival data available in GEO were included in this 
study. The datasets were pre-processed as previously 
described using R and Bioconductor for normalization 
[71]. Information about the patients and breast cancer 
samples can be found on the GEO website. All these 
data sets were used to generate the Kaplan-Meier curves. 
The combined breast cancer dataset consisted of 1096 
patients. The patients were first split into two groups 
by the median expression value of RAN (or VEGFR2), 
resulting in a RAN-high group and a RAN-low group. 
Then within each group the patients were split by the 
median expression value of the other gene, VEGFR2 
(or correspondingly RAN), into two sub-groups, for 
which two Kaplan-Meier curves were created. Wald test 
were used to assess if they were significantly different. 
The low or high expression status is determined by the 
median expression level, above which is considered as 
“high” and below the median is “low” expression. The 
correlation in expression between Ran and VEGF2 was 
assessed using Pearson’s correlation analysis, based 
on the same sets of GEO data series used to generate 
Kaplan-Meier curves with an additional data series 
GSE11121 [72]. The latter was not used in the combined 
survival analysis, because GSE11121 has metastasis-free 
survival data rather than relapse-free survival data as the 
other 5 data series.
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